Getinge AB

GETI B

Equity

ISIN SE0000202624 / Valor 84926

NASDAQ Nordic Exchange Stockholm, Equities (2024-11-19)

SEK 171.10-0.90%

Getinge AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Getinge AB is a leading company in the field of cardiology, offering a wide range of products and services for operating rooms. Through strategic acquisitions and organic growth, Getinge has become a key player in Acute Care Therapies, Life Science, and Surgical Workflows. The company's history dates back to 1838, with the acquisition of Maquet in 2000 further enhancing its presence in operating theatres. Getinge's focus on innovation and patient-centric solutions, such as heart-lung machines and ventilators, has solidified its position in the market. With a strong financial foundation and a history of continuous sales growth since its listing in 1993, Getinge is a prominent player in the medical technology industry.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Overview

In the first quarter of 2024, Getinge AB reported a stable organic net sales growth of 0.0%, maintaining the same level as the previous year. The total revenue for the quarter was SEK 7,513 million, showing a slight increase from SEK 7,141 million in the first quarter of 2023. This stability in revenue highlights the company's consistent performance amidst varying market conditions.

Earnings Performance

Getinge AB experienced a decrease in adjusted EBITA during the first quarter of 2024, amounting to SEK 842 million compared to SEK 972 million in the same quarter of the previous year. This represents a decline in the EBITA margin from 13.6% to 11.2%, primarily due to increased costs for input goods and personnel, as well as ongoing expenses related to quality improvements in specific product lines.

Profitability Metrics

The adjusted gross profit for Getinge AB in Q1 2024 was SEK 3,855 million, slightly up from SEK 3,734 million in Q1 2023, with the gross margin slightly decreasing from 52.3% to 51.3%. This marginal decline in profitability percentage points towards increased operational costs that could not be completely offset by revenue growth.

Dividend and Share Performance

Getinge AB reported adjusted earnings per share of SEK 1.92 in the first quarter of 2024, a decrease from SEK 2.34 in the same quarter of the previous year. This reduction reflects the overall decrease in profitability but shows a sustained capacity to generate earnings amidst financial pressures.

Future Outlook

Looking ahead into 2024, Getinge AB expects organic sales growth to be between 2% and 5%. This forecast underscores the company's cautious optimism about its performance in the coming periods, despite the current challenges and increased operational costs impacting the healthcare and technology sectors globally.

Summarized from source with an LLMView Source

Key figures

-21.9%1Y

-58.0%3Y

6.31%5Y

Performance

33.2%1Y

37.7%3Y

36.2%5Y

Volatility